Á¦ 3±âÀÇ ÁøÇ༺ ºñ¼Ò¼¼Æ÷ Æó¾Ï¿¡¼ÀÇ MVP º¹ÇÕ Ç×¾Ï ¿ë¹ý°ú ´ÙºÐÇÒ ¹æ»ç¼± Ä¡·á - Ãß°¡ Ç×¾Ï ¿ä¹ý¿¡ ´ëÇÑ ÀÓÀÇ ¼±ÅÃ-
MVP Chemotherpy and Hyperfractionated Radiotherapy for Stage ¥² Unresectable Non-Small Cell Lung Cancer
´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1991³â 9±Ç 2È£ p.215 ~ p.219
ÃÖÀº°æ(Choi Eun-Kyung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø Ä¡·á¹æ»ç¼±°úÇб³½Ç
À̱ÔÇü(Lee Kyoo-Hyung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
ÀÌÁ¤½Å(Lee Jung-Shin) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
±è»óÈñ(Kim Sang-Hee) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
ÀåÇý¼÷(Chang Hye-Sook) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø Ä¡·á¹æ»ç¼±°úÇб³½Ç
±è¿ì¼º(Kim Woo-Sung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
±è¿øµ¿(Kim Won-Dong) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
¼Õ±¤Çö(Sohn Kwang-Hyun) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ÈäºÎ¿Ü°úÇб³½Ç
¼Ã¶¿ø(Suh Chul-Won) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
ÃÖöÁØ(Choi Chul-Joon) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
°íÀ±¼®(Koh Youn-Suck) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ³»°úÇб³½Ç
±è»ïÇö(Kim Sam-Hyun) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïÁß¾Óº´¿ø ÈäºÎ¿Ü°úÇб³½Ç
Abstract
To evaluate the effect of MVP chemotherapy and hyperfractionated radiotherapy in Stage ¥² unresectable non small cell lung cancer (NSCLC), authors have conducted a prospective randomized study since January 1991. Stage ¥²a or ¥²b unresectable NSCLC patients were treated with hyperfractionated radiotherapy (120 cGy/fx BID) up to 6500 cGY following 3 cycles of induction MVP (Mitomycin C 6 mg/§³, vinblastine 6 mg/§³, Cisplatin 60 mg/§³) and randomized for either oservation or 3 cycles of maintenance MVP chemotherapy. Until August 1991, 18 patients were registered to this study. 4 cases were stage ¥²a and 14 were stage ¥²b.
Among 18 cases 2 were lost after 2 cycles of chemotherapy, and 16 were analyzed for this preliminary report. The response rate of induction chemotherapy was 62.5%; partial response, 50% and minimal response, 12.5%. Residual tumor of the one partial responder was completely disappeared after radiotherapy. Among 6 cases who were progressed during induction chemotherapy, 4 of them were also progressed after radiotherapy.
All patients were tolerated BID radiotherapy without definite increase of acute complications, compared with conventional radiotherapy group. But at the time of this report, one patient expired in two month after the completion of the radiotherapy because of treatment related complication.
Although the longer follow up is needed, authors are encouraged with higher response rate and acceptable toxicity of this treatment. Authors believe that this study is worthwhile to continue.
Å°¿öµå
NSCLC, MVP chemotherapy, Hyperfractionated radiotherapy
KMID :
0362919910090020215
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The response rate of induction chemotherapy was 62.5%; partial response, 50% and minimal response, 12.5%. Residual tumor of the one partial responder was completely disappeared after radiotherapy.